A vaccine developer from Nigeria, Dr Simon Agwale Friday in Paris, France, presented his progress report on Ebola vaccine saying that he "developed an EBOV candidate vaccine that is highly immunogenic in mice."

 

Dr Agwale is among over 300 delegates drawn from forty-two countries to mark the International Conference on Targeting Ebola organised by the Pasteur Institute held weekend.

 

A statement by Dr Yuri Nakamoto, on behalf of the Scientific Committee of the conference, said the agenda included 140 oral, short and posters communications, latest developments in the Ebola outbreak in Africa, latest clinical developments, innovations, vaccines and drugs to combat Ebola, and prevention of Ebola contamination and transmission, to be published by the committee.

 

 

Dr Agwale alongside Epie E, and Pushko P, of Innovative Biotech Ltd, Keffi, Nasarawa State, Nigeria; and Innovative Biotech USA Inc.

 

Havre de Grace MD USA, in their presentation entitled, "Construction and Evaluation of a Highly Immunogenic EBOLA Influenza VLP Vaccine Candidate", prepared and evaluated EBOV VLPs that included GP of EBOV Zaire strain in which VLPs were expressed using recombinant baculovirus in Sf9 cells.